Filing Flows › Maxcyte (MXCT) › Assay and other service revenue revenue
Maxcyte (MXCT) Assay and other service revenue revenue by quarter
Maxcyte's Assay and other service revenue revenue was $583K in Q2 2026 (second quarter 2026), +21% from Q1 2026. Over the last 6 quarters it ranged from $310K (Q2 2025) to $650K (Q3 2025).
| Quarter | Assay and other service revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $583K | +21% | +88% |
| Q1 2026 | $482K | -21% | +21% |
| Q4 2025 | $609K | -6% | — |
| Q3 2025 | $650K | +110% | — |
| Q2 2025 | $310K | -22% | — |
| Q1 2025 | $397K | — | — |
Q2 2026 at a glance
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Maxcyte's Assay and other service revenue revenue?
Maxcyte's Assay and other service revenue revenue was $583K in Q2 2026 (second quarter 2026), +21% from Q1 2026.
How has Maxcyte's Assay and other service revenue revenue changed?
Over the last 6 quarters it ranged from $310K (Q2 2025) to $650K (Q3 2025).